Get the Stockscreener App
7.61
6.05%
-0.49
After Hours:
7.61
Enanta Pharmaceuticals Inc stock is traded at $7.61, with a volume of 276.29K.
It is down -6.05% in the last 24 hours and up +0.66% over the past month.
Enanta Pharmaceuticals Inc is an American biotechnology company which uses robust, chemistry-driven approach and drug discovery capabilities to focus on the research and development of molecule drugs to cure viral infections and liver diseases. Uses virology and immunology method for curing the diseases. The targeted diseases are hepatitis C, hepatitis B, nonalcoholic steatohepatitis, and the respiratory syncytial virus. The novelty of company research is a specific direct-acting antiviral inhibitor against the hepatitis C virus. The company's inhibitors have been developed in collaboration with AbbVie. AbbVie markets the protease inhibitor, paritaprevir, while other inhibitors are in the pipeline.
See More
Previous Close:
$8.10
Open:
$8.18
24h Volume:
276.29K
Relative Volume:
1.72
Market Cap:
$162.68M
Revenue:
$66.59M
Net Income/Loss:
$-104.93M
P/E Ratio:
-1.5374
EPS:
-4.95
Net Cash Flow:
$-96.48M
1W Performance:
-1.55%
1M Performance:
+0.66%
6M Performance:
+48.05%
1Y Performance:
-48.41%
1-Day Range:
$7.5638
$8.31
1-Week Range:
$7.15
$8.31
52-Week Range:
$4.09
$15.17
Enanta Pharmaceuticals Inc Stock (ENTA) Company Profile
Name
Enanta Pharmaceuticals Inc
Sector
Industry
Phone
617 607 0800
Address
4 KINGSBURY AVENUE, WATERTOWN, MA
Compare ENTA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ENTA
Enanta Pharmaceuticals Inc
|
7.61 | 173.15M | 66.59M | -104.93M | -96.48M | -4.95 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.16 | 120.29B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
554.58 | 60.26B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
339.80 | 43.10B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
598.89 | 36.65B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
299.94 | 33.09B | 3.81B | -644.79M | -669.77M | -6.24 |
Enanta Pharmaceuticals Inc Stock (ENTA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-09-23 | Downgrade | JP Morgan | Neutral → Underweight |
| Aug-08-23 | Downgrade | Jefferies | Buy → Hold |
| Dec-09-22 | Initiated | H.C. Wainwright | Buy |
| Jul-06-22 | Upgrade | Evercore ISI | In-line → Outperform |
| Jun-01-22 | Upgrade | Evercore ISI | Underperform → In-line |
| Oct-07-21 | Initiated | Jefferies | Buy |
| Sep-09-21 | Initiated | SVB Leerink | Mkt Perform |
| Jan-29-21 | Upgrade | JP Morgan | Underweight → Neutral |
| Nov-24-20 | Initiated | Evercore ISI | Underperform |
| Aug-28-20 | Resumed | ROTH Capital | Buy |
| Aug-26-20 | Initiated | Piper Sandler | Overweight |
| Jul-27-20 | Upgrade | JMP Securities | Mkt Perform → Mkt Outperform |
| Mar-17-20 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Nov-22-19 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Sep-26-19 | Downgrade | JP Morgan | Neutral → Underweight |
| May-24-19 | Initiated | Wolfe Research | Outperform |
| Apr-23-19 | Upgrade | Berenberg | Hold → Buy |
| Dec-13-18 | Initiated | Berenberg | Hold |
| Jun-06-18 | Initiated | ROTH Capital | Buy |
| Feb-08-18 | Downgrade | JP Morgan | Overweight → Neutral |
| Jan-02-18 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Nov-21-17 | Reiterated | RBC Capital Mkts | Outperform |
| Sep-15-17 | Initiated | RBC Capital Mkts | Outperform |
| Jul-11-17 | Upgrade | JMP Securities | Mkt Perform → Mkt Outperform |
| Apr-28-16 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Feb-09-16 | Reiterated | Barclays | Underweight |
| Oct-23-15 | Downgrade | Barclays | Equal Weight → Underweight |
| Oct-23-15 | Upgrade | JMP Securities | Mkt Perform → Mkt Outperform |
View All
Enanta Pharmaceuticals Inc Stock (ENTA) Latest News
What makes Enanta Pharmaceuticals Inc. stock price move sharplyFree Risk Managed Intraday Trade Alerts - Newser
Can a trend reversal in Enanta Pharmaceuticals Inc. lead to recovery3-Day Market Movement Forecast Analysis - Newser
How institutional ownership impacts Enanta Pharmaceuticals Inc. stockPattern Recognition Tool for ROI Investors - Newser
Enanta Pharmaceuticals Inc. Stock Chart Analysis: Bullish or Bearish Pattern FormingWeekly Growth Portfolio Performance Summary - Newser
Enanta Pharmaceuticals Announces Closing of Initial Public Offering and Exercise of Underwriters' Ov - AOL.com
Enanta Pharmaceuticals Inc. stock prediction for this weekROI Prediction from Long-Term Holding Plans - Newser
Can volume confirm reversal in Enanta Pharmaceuticals Inc.Risk/Reward Optimization Entry Point Analysis - Newser
Will Enanta Pharmaceuticals Inc. stock benefit from interest rate changesFree Fundamental + Technical Hybrid Stock Tips - Newser
How Interest Rate Changes Impact Enanta Pharmaceuticals Inc. Stock PerformanceFree Early Entry Tips With Low Risk Zone - Newser
Will Enanta Pharmaceuticals Inc. Stock Benefit from AI and Green Energy TrendsMachine Learning Stock Price Forecast Tool - Newser
How Enanta Pharmaceuticals Inc. stock performs during market volatilityDaily Entry Opportunity Forecasting Tool - Newser
Is Enanta Pharmaceuticals Inc. a growth stock or a value stockBeginner Investor Growth Plan For Every Investor - jammulinksnews.com
Does Enanta Pharmaceuticals Inc. stock perform well during market downturnsUnlock exclusive stock market forecasts - jammulinksnews.com
What institutional investors are buying Enanta Pharmaceuticals Inc. stockGet real-time updates on market trends - jammulinksnews.com
How does Enanta Pharmaceuticals Inc. compare to its industry peersGet daily updates on the hottest stocks - jammulinksnews.com
Enanta Pharmaceuticals stock receives Buy rating from H.C. Wainwright By Investing.com - Investing.com Canada
What are Enanta Pharmaceuticals Inc. company’s key revenue driversRapid-fire capital growth - jammulinksnews.com
Is Enanta Pharmaceuticals Inc. stock overvalued or undervaluedInvest smarter with actionable stock recommendations - jammulinksnews.com
What catalysts could drive Enanta Pharmaceuticals Inc. stock higher in 2025Identify undervalued stocks ready to soar - jammulinksnews.com
What is Enanta Pharmaceuticals Inc. company’s growth strategyFree Smart Trading Workshop - jammulinksnews.com
Is it the right time to buy Enanta Pharmaceuticals Inc. stockOverwhelming financial success - jammulinksnews.com
Enanta Pharmaceuticals Inc. Company’s Quarterly Earnings Growth: What the Numbers SayProven Trading Plan - metal.it
How many analysts rate Enanta Pharmaceuticals Inc. as a “Buy”Invest smarter with actionable stock recommendations - jammulinksnews.com
Intrinsic Value of Enanta Pharmaceuticals Inc. Stock: Is It Undervalued or OvervaluedWealth Accumulation Stock List - Newser
Enanta Pharmaceuticals Inc. Company Revenue and Profit Trends: A Deep DiveFast Gains With Reduced Risk - Newser
Has Enanta Pharmaceuticals Inc. Stock Ever Crashed Historical Volatility ReviewLow Risk Consistent Winners - Newser
What drives Enanta Pharmaceuticals Inc. stock priceStrong return on investment - Autocar Professional
One Enanta Pharmaceuticals Insider Raised Their Stake In The Previous Year - Yahoo Finance
What analysts say about Enanta Pharmaceuticals Inc. stockJaw-dropping returns - Autocar Professional
Is Enanta Pharmaceuticals Inc. a good long term investmentMarket-crushing stock picks - PrintWeekIndia
Enanta Pharmaceuticals Inc Stock (ENTA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.23%
0.40%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):